A detailed history of Group One Trading, L.P. transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 5,395 shares of AQST stock, worth $19,691. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,395
Holding current value
$19,691
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.4 - $5.09 $12,948 - $27,460
5,395 New
5,395 $26,000
Q2 2023

Aug 09, 2023

BUY
$1.06 - $2.49 $546 - $1,284
516 Added 193.26%
783 $1,000
Q1 2023

May 12, 2023

SELL
$0.72 - $1.15 $17,275 - $27,593
-23,994 Reduced 98.9%
267 $0
Q4 2022

Feb 09, 2023

SELL
$0.77 - $1.18 $4,374 - $6,703
-5,681 Reduced 18.97%
24,261 $21,000
Q3 2022

Nov 09, 2022

SELL
$0.63 - $1.73 $9,044 - $24,837
-14,357 Reduced 32.41%
29,942 $35,000
Q2 2022

Aug 11, 2022

SELL
$0.64 - $2.57 $5,089 - $20,439
-7,953 Reduced 15.22%
44,299 $28,000
Q1 2022

May 12, 2022

SELL
$2.28 - $4.26 $55,041 - $102,840
-24,141 Reduced 31.6%
52,252 $136,000
Q4 2021

Feb 11, 2022

BUY
$3.69 - $6.37 $223,473 - $385,779
60,562 Added 382.55%
76,393 $297,000
Q3 2021

Nov 12, 2021

BUY
$3.25 - $4.66 $5,976 - $8,569
1,839 Added 13.14%
15,831 $69,000
Q2 2021

Aug 10, 2021

SELL
$3.29 - $5.21 $39,470 - $62,504
-11,997 Reduced 46.16%
13,992 $56,000
Q1 2021

May 12, 2021

BUY
$4.17 - $6.73 $108,374 - $174,905
25,989 New
25,989 $135,000
Q4 2020

Feb 10, 2021

SELL
$4.65 - $7.79 $590 - $989
-127 Closed
0 $0
Q3 2020

Nov 12, 2020

SELL
$4.12 - $9.09 $28,460 - $62,793
-6,908 Reduced 98.19%
127 $1,000
Q2 2020

Aug 13, 2020

BUY
$1.84 - $6.44 $12,944 - $45,305
7,035 New
7,035 $34,000

Others Institutions Holding AQST

About Aquestive Therapeutics, Inc.


  • Ticker AQST
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,350,700
  • Market Cap $195M
  • Description
  • Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...
More about AQST
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.